---
title: Cellulitis Treatment
---
# Cellulitis Treatment

(NEJM 2014;370:2238; CID 2014;59:e10; JAMA 2016;316:325 & 2017;317:2088)
| Purulent | Usual Micro | Severity | Treatment |

## ![IDSA Algorithm for Management of SSTI](https://i.imgur.com/JahzGmi.png)

## No Purulent
* Necrotizing Infection / Cellulitis / Erysipelas
Î²-hemolytic Strep >S. aureus

### Mild: Oral: PCN VK, cephalosporin, Dicloxacillin, Clindamycin
### Mod: IV: PCN, ceftriaxone, cefazolin, Clindamycin
### Severe: IV: vanc + pip/tazo (Â± clinda for toxic shock syndrome)
### åš´é‡çš„æ„ŸæŸ“ï¼Œè¦æ—©é»ç¢ºå®šè¨ºæ–·ï¼Œè¦æ’é™¤ä¸æ˜¯Necrotizing Fasciitis
* Monomicrobial  (å˜´ç‚®æ™‚é–“ï¼šæ ¹æ“š2014 IDSA guideline non-purulent cellulitisï¼Œåš´é‡æ„ŸæŸ“å¸¸è¦‹çš„ç—…åŸèŒæœ‰Strep pyogenes, Clostridial, Vibrio...ï¼Œé¦–é¸çš„æ²»ç™‚ä¸»è¦æ˜¯PenicillinåŠ ä¸ŠClindaï¼Œå¦å¤–çš„é¸é …ä¹Ÿæœ‰Doxycycline, Ceftz, Cipro)
	* Strep pyogenes
	* Clostridial sp.
	* Vibrio vulnificus
	* Aeromonas hydrophila
qv: ç†±ç—… [[Acute bacterial skin and skin structure infections]]
## Yes Purulent
> å¦‚æœå·²ç¶“æœ‰è†¿ï¼Œé€™æ™‚æˆ‘ä¸æœƒæŠŠè¨ºæ–·å«cellulitisï¼Œè¦å«furnucle, carbuncle, abscess

 S. aureus (incl. MRSA) >> Î²-hemolytic Strep 
> æœƒé€ æˆé€™æ¨£åš´é‡çš„æ„ŸæŸ“ï¼Œæœ€éœ€è¦æ’é™¤çš„å°±æ˜¯MRSAï¼ŒåŒæ™‚ä¸€å®šè¦æ‰¾æ•´å¤–è©•ä¼°ï¼Œçœ‹æ˜¯å¦è¦åšåˆ‡é–‹æµ

### Mild: Consider I&D only vs. I&D + clinda or TMP-SMX (NEJM 2017;376:2545)
### Mod: I&D + TMP-SMX or doxycycline
### Severe: I&D + IV vanc, daptomycin or linezolid (Â± clinda for toxic shock syndrome)
* åœ¨åš´é‡çš„æ„ŸæŸ“ï¼Œç­‰å¾…åŸ¹é¤Šå‡ºä¾†å‰ï¼Œæˆ‘æœƒå…ˆç¶“é©—æ€§çµ¦å¾Œç·šå¯ä»¥Cover MRSAæŠ—ç”Ÿç´ ï¼Œ
* å¦‚Vancomycin, Dpatomycin, Linezolid, Ceftaroline, ç•¶ç„¶Baktarä¹Ÿæ˜¯å¯ä»¥è€ƒæ…®ä¸€ä¸‹
* å¦‚æœçµæœæ˜¯MSSAï¼Œå°±å¯ä»¥è€ƒæ…®é™

> Mild: abscess <2 cm, no systemic signs of infection, immunocompetent, no indwelling hardware;
> moderate: systemic signs;
> severe: SIRS or immunosuppressed


> å„˜ç®¡ç›®å‰çš„æŒ‡å—å»ºè­°å°å°æ–¼ 2 cm çš„å–®ç´”åŒ–è†¿æ€§è†¿è…«å–®ç¨åˆ‡é–‹å¼•æµï¼Œä½†æœ€è¿‘çš„æ•¸æ“šè¡¨æ˜ï¼Œå³ä½¿åœ¨è¼ƒå°çš„è†¿è…«ä¸­ï¼Œè¼”åŠ©æŠ—ç”Ÿç´ æ²»ç™‚ä¹Ÿå¯èƒ½å°è‡´æ›´é«˜çš„æ²»æ„ˆç‡ã€‚å°æ–¼è¼ƒå¤§çš„è†¿è…«ï¼Œéœ€è¦é€²è¡Œè¼”åŠ©æŠ—èŒæ²»ç™‚ã€‚
> ç”¨ğŸ¦ çš„è©±èªªï¼šå°±æ˜¯å°æ–¼2cmé›–ç„¶guidelineèªªæ˜¯å¼•æµå°±å¥½ï¼Œä½†æœ‰æŠ—ç”Ÿç´ å¥½å¾—å¿«

* Limb elevation; erythema may worsen after starting abx b/c bacterial killing â†’ inflam.
	* è‚¢é«”æŠ¬é«˜ï¼›é–‹å§‹ abx b/c ç´°èŒæ®ºæ»… â†’ ç™¼ç‚å¾Œï¼Œç´…æ–‘å¯èƒ½æœƒæƒ¡åŒ–ã€‚
* In obese Pts, adequate drug dosing important to avoid treatment failure (J Infect 2012;2:128)
* Duration: 5 to up to 14 d based on severity and response to treatment. Take pictures & draw margins to track progress.
